Your browser doesn't support javascript.
loading
The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer.
Leeksma, Alexander C; Derks, Ingrid A M; Kasem, M Haidar; Kilic, Emine; de Klein, Annelies; Jager, Martine J; van de Loosdrecht, Arjan A; Jansen, Joop H; Navrkalova, Veronika; Faber, Laura M; Zaborsky, Nadja; Egle, Alexander; Zenz, Thorsten; Pospisilova, Sarka; Abdel-Wahab, Omar; Kater, Arnon P; Eldering, Eric.
Afiliação
  • Leeksma AC; Department of Hematology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.
  • Derks IAM; Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.
  • Kasem MH; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), Amsterdam, Netherlands.
  • Kilic E; Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.
  • de Klein A; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), Amsterdam, Netherlands.
  • Jager MJ; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • van de Loosdrecht AA; Department of Ophthalmology and Clinical Genetics Erasmus MC, Rotterdam, Netherlands.
  • Jansen JH; Department of Ophthalmology and Clinical Genetics Erasmus MC, Rotterdam, Netherlands.
  • Navrkalova V; Department of Ophthalmology, LUMC, Leiden, Netherlands.
  • Faber LM; Department of Hematology, Amsterdam University Medical Centers, Location VUMC, Amsterdam, Netherlands.
  • Zaborsky N; Laboratory of Hematology, Department Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Egle A; Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Center of Molecular Medicine, CEITEC, Masaryk University, Brno, Czechia.
  • Zenz T; Department of Internal Medicine, Rode Kruis Ziekenhuis, Beverwijk, Netherlands.
  • Pospisilova S; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
  • Abdel-Wahab O; Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria.
  • Kater AP; Department of Internal Medicine III with Haematology, Cancer Cluster Salzburg, Salzburg, Austria.
  • Eldering E; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Front Oncol ; 10: 609409, 2020.
Article em En | MEDLINE | ID: mdl-33585229
ABSTRACT
Recurrent mutations in splicing factor 3B subunit 1 (SF3B1) have been identified in several malignancies and are associated with an increased expression of 3' cryptic transcripts as a result of alternative branchpoint recognition. A large fraction of cryptic transcripts associated with SF3B1 mutations is expected to be sensitive for RNA degradation via nonsense-mediated mRNA decay (NMD). Several studies indicated alterations in various signaling pathways in SF3B1-mutated cells, including an impaired DNA damage response (DDR) in chronic lymphocytic leukemia (CLL). In this study, we investigated isogenic cell lines and treatment naïve primary CLL samples without any TP53 and/or ATM defect, and found no significant effects of SF3B1 mutations on the ATM/p53 response, phosphorylation of H2AX and sensitivity to fludarabine. Cryptic transcripts associated with SF3B1 mutation status were observed at relatively low levels compared to the canonical transcripts and were validated as target for mRNA degradation via NMD. Expression of cryptic transcripts increased after NMD inhibition. In conclusion, our results confirm involvement of NMD in the biological effects of SF3B1 mutations. Further studies may elucidate whether SF3B1-mutant patients could benefit from NMD modulatory agents.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda